Zacks Research Issues Optimistic Estimate for NKTR Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Zacks Research lifted their Q1 2025 EPS estimates for shares of Nektar Therapeutics in a report released on Wednesday, April 2nd. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will earn ($0.17) per share for the quarter, up from their previous forecast of ($0.21). The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.70) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.84) EPS.

A number of other analysts have also weighed in on the stock. Oppenheimer raised shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research report on Friday, March 14th. William Blair reiterated a “market perform” rating on shares of Nektar Therapeutics in a report on Thursday, March 13th. B. Riley started coverage on Nektar Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $4.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.50 target price on shares of Nektar Therapeutics in a research note on Thursday, March 13th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $4.92.

Nektar Therapeutics Stock Performance

Shares of Nektar Therapeutics stock opened at $0.49 on Monday. The stock has a market cap of $91.27 million, a price-to-earnings ratio of -0.58 and a beta of 0.69. The stock has a 50 day moving average price of $0.81 and a 200-day moving average price of $1.02. Nektar Therapeutics has a one year low of $0.47 and a one year high of $1.93.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, March 12th. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.33. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%. The company had revenue of $29.18 million during the quarter, compared to analyst estimates of $36.65 million.

Institutional Investors Weigh In On Nektar Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NKTR. Nantahala Capital Management LLC increased its holdings in shares of Nektar Therapeutics by 90.0% during the fourth quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company’s stock valued at $7,263,000 after acquiring an additional 3,700,000 shares in the last quarter. Woodline Partners LP grew its position in Nektar Therapeutics by 187.3% during the 4th quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company’s stock worth $4,626,000 after purchasing an additional 3,242,841 shares during the last quarter. Altium Capital Management LLC grew its position in Nektar Therapeutics by 26,172.0% during the 4th quarter. Altium Capital Management LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock worth $2,790,000 after purchasing an additional 2,988,581 shares during the last quarter. 22NW LP acquired a new position in Nektar Therapeutics during the 4th quarter valued at approximately $2,038,000. Finally, Peapod Lane Capital LLC purchased a new position in shares of Nektar Therapeutics in the fourth quarter worth $1,030,000. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.